DTIL Receives FDA Clearance for PBGENE-DMD, Enabling Phase 1/2 Clinical Trial for Duchenne Muscular Dystrophy
Precision BioSciences, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.02
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS